- The FDA has signed off TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) initiation of a Phase 1/2 trial of YH001 in combination with envafolimab and doxorubicin in sarcoma patients, including those who have not received prior therapy.
- The Phase 1/2 trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma.
- Related: TRACON Pharma, Eucure Join Forces To Develop CTLA-4 Antibody For Oncology Indications.
- Additionally, the safety and efficacy of YH001, envafolimab, and doxorubicin will be assessed in the more prevalent sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.
- YH001, an IgG1 antibody against CTLA-4, has shown enhanced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
- Price Action: TCON shares are up 0.50% at $2.02 on the last check Monday.
Peering Into Valero Energy’s Recent Short Interest
Valero Energy’s (NYSE:VLO) short percent of float has risen 5.01% since its last report. The company recently reported…
